Full Press Release Details
NEW YORK, NY--(Marketwire - August 21, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) announced
today that the Swedish Medical Center in Englewood, Colorado, has joined
Delcath's Phase III clinical trial for the treatment of metastatic melanoma
in the liver. Swedish Medical Center is the ninth center to join this
multi-center trial testing the Company's Percutaneous Hepatic Perfusion
(PHP) System for the isolated, high-dose delivery of the anti-cancer agent
Delcath and Swedish Medical Center have entered into a clinical research
agreement to conduct the Phase III National Cancer Institute (NCI) led
study. Dr. Charles Nutting, an interventional radiologist specializing in
minimally invasive cancer treatment, will serve as the Principal
Investigator. Commenting on joining this trial, Dr. Nutting stated, "PHP
offers a unique and highly promising treatment modality for patients
suffering from melanoma that has metastasized to the liver. Regional
liver-directed therapy has shown tremendous success for patients suffering
from primary and metastatic disease, and PHP offers an approach to
treatment of the entire liver which has previously been lacking. I look
forward to being able to provide this treatment to my patients, and to
working with the technology as the Company explores the possibility for
expanded use of its System."
On Swedish Medical Center joining this trial, Richard L. Taney, President
and CEO of Delcath, stated, "Dr. Nutting is a welcome addition to this
trial and we are excited to be working with him. Dr. Nutting has been a
leader in the development and use of regional cancer treatment modalities
for many years and brings great experience and valuable leadership to this
trial. Located immediately Southwest of Denver, Colorado, Swedish Medical
Center is ideally situated to allow Delcath's PHP treatment to reach an
important geographic region and will further advance our goal of completing
enrollment of this trial in 2009."
About Swedish Medical Center
Swedish Medical Center is an acute care hospital with 368 licensed beds
located in the South Denver metro area in Englewood, Colorado, where it has
been a proud member of the community for more than 100 years. The Mission
of Swedish Medical Center is to provide compassionate, high-quality patient
care that meets the caring and cost effective expectations of our patients,
physicians, employees and volunteers, and to preserve and strengthen the
Swedish tradition of community service. The Vision of Swedish Medical
Center is to become the provider of choice of healthcare services for our
community. We will differentiate ourselves in the community from other
healthcare providers through our centers of excellence: Neurosciences, in
collaboration with the Colorado Neurological Institute, Adult and Pediatric
Trauma Services, Cardiology Services, Cancer Treatment Services, Advanced
Radiology Capabilities, and Women's and Children's Services.
About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical technology company specializing in
cancer treatment. The Company has developed a proprietary, patented system
which will improve the efficacy of cancer treatment while reducing the
considerable, systemic side-effects of chemotherapy. Delcath's novel drug
delivery platform is capable of delivering anti-cancer drugs at very high
doses to a specific organ or region of the body while preventing these high
doses of drug from entering the patient's bloodstream. The Company is
currently enrolling patients in Phase III and Phase II clinical studies for
the treatment of liver cancers using high doses of melphalan. The
Company's intellectual property portfolio consists of twenty-eight patents
on a worldwide basis including the U.S., Europe, Asia and Canada. For more
information, please visit the Company's website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor
for forward-looking statements made by the Company or on its behalf. This
news release contains forward-looking statements, which are subject to
certain risks and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating to our ability to
successfully complete Phase III clinical trials and secure regulatory
approval of our current or future drug-delivery system and uncertainties
regarding our ability to obtain financial and other resources for any
research, development and commercialization activities. These factors, and
others, are discussed from time to time in our filings with the Securities
and Exchange Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date they are made.
We undertake no obligation to publicly update or revise these
forward-looking statements to reflect events or circumstances after the
Contact Information: Company Contact:
Delcath Systems, Inc.
Investor Relations Contact:
Strategic Growth International, Inc.
Public Relations Contact:
Rubenstein Associates, Inc.